Back

The role of soluble st2 and galectin-3 in hypertrophic cardiomyopathy assessed by cardiac magnetic resonance

29 April 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 4 - Hypertrophic cardiomyopathy Hypertrophic cardiomyopathy HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Doctor Monika Gawor

Institute of Cardiology, Warsaw (Poland)

5 More presentations in this session

Presentation thumbnail
Predictors of ICD-related adverse events in patients with hypertrophic cardiomyopathy
Mr C. Klein (Lille, FR)
Presentation thumbnail
Impact of hypertrophy in left ventricular ejection fraction and myocardial strain: application of three-dimensional wall-motion tracking technology in hypertrophic cardiomyopathy
Doctor L. Marques (Sra. da Hora, PT)
Abstract
Presentation thumbnail
Assessment of left ventricular strain by three-dimensional wall-motion tracking technology: a study in hypertrophic cardiomyopathy
Doctor L. Marques (Sra. da Hora, PT)
Abstract
Presentation thumbnail
Brain natriuretic peptide level in patients with hypertrophic cardiomyopathy
Mrs A. Demkina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Myosin heavy chain and MAP-kinase activating death domain-containing gene polymorphisms in adults with hypertrophic cardiomyopathy
Miss A. Polyakova (Saint Petersburg, RU)

Access the full session

Session thumbnail
Poster Session 4 - Hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources